Thioridazine (Mellaril): why it was withdrawn from front-line use

Thioridazine, marketed as Mellaril by Sandoz/Novartis from the late 1950s, was for decades one of the most heavily prescribed antipsychotics in the United States. It was widely used because it produced less acute movement-side-effect burden than haloperidol or chlorpromazine. Then, beginning in 2000, regulators in multiple countries restricted its use after consistent evidence that it could prolong the QT interval on ECG and cause sudden cardiac death. The drug is still listed in some pharmacopoeias and is occasionally used, but its place in mainstream practice is essentially gone.

Why it was popular

Compared with high-potency typicals such as haloperidol or fluphenazine, thioridazine produced markedly less acute extrapyramidal symptoms — less rigidity, less akathisia, less acute dystonia. For decades that was a major selling point. It was also strongly sedating and had a useful place in calming agitated patients on inpatient wards. By the 1980s it was one of the most prescribed antipsychotics in many Western countries.

What changed

Two safety problems became increasingly clear during the 1990s:

QT prolongation and sudden cardiac death

Thioridazine produces a dose-dependent prolongation of the QT interval on ECG, more pronounced than most other antipsychotics. This translated, in observational and post-marketing data, into excess sudden cardiac death. The FDA issued a black box warning in 2000 explicitly limiting thioridazine to schizophrenia patients who had failed other antipsychotic treatment, and required ECG monitoring before and during use. The UK's MHRA and other regulators followed.

Pigmentary retinopathy

At doses above roughly 800 mg per day, thioridazine can cause a pigmentary retinopathy that can lead to permanent vision loss. The FDA label has long included a maximum recommended daily dose of 800 mg precisely for this reason.

How it works pharmacologically

Thioridazine is a piperidine phenothiazine. It blocks dopamine D2 receptors, with substantial affinity for histamine H1 (sedation), muscarinic acetylcholine (dry mouth, constipation, blurred vision), and alpha-1 adrenergic receptors (orthostatic hypotension). Like chlorpromazine it is "low-potency" — doses are in the hundreds of milligrams. The ECG-related toxicity is thought to relate primarily to blockade of cardiac hERG potassium channels.

Current FDA-restricted indication

Per the modern DailyMed labelling, thioridazine is indicated only for "schizophrenic patients who fail to show an acceptable response to adequate courses of treatment with other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects." The label requires baseline ECG and electrolytes and explicitly contraindicates use with other QT-prolonging medications and in patients with congenital long QT syndrome, history of cardiac arrhythmias, or significant electrolyte disturbance.

Drug interactions of particular concern

Thioridazine is metabolised in part by CYP2D6. Strong CYP2D6 inhibitors (fluoxetine, paroxetine) can dramatically raise thioridazine levels and worsen QT prolongation. People who are CYP2D6 poor metabolisers are also at higher risk. Other QT-prolonging drugs (some antibiotics like macrolides and fluoroquinolones, methadone, several antiarrhythmics) substantially compound the risk.

Side effects beyond cardiac and ophthalmic

• Sedation, dry mouth, constipation, urinary retention, blurred vision
• Orthostatic hypotension, falls in older adults
• Sexual dysfunction including, classically, retrograde ejaculation in men
• Weight gain
• Hyperprolactinemia
• EPS — generally less than with high-potency typicals but still possible
• Tardive dyskinesia with chronic use

Where it stands today

In most high-income countries, thioridazine is essentially no longer prescribed. NICE and APA guidance do not recommend it for schizophrenia. Some pharmacies have removed it from formularies entirely. In a few low- and middle-income settings, generic thioridazine remains available, and isolated use continues in patients who have done poorly on alternatives. Even in those cases, the modern standard is to try clozapine — a far better-evidenced option in treatment-resistant schizophrenia — before defaulting to thioridazine.

Why this story matters

Thioridazine's withdrawal is a useful reminder of how antipsychotic safety knowledge has evolved. For roughly 40 years it was used in millions of people. Only as ECG monitoring became routine and post-marketing surveillance improved did the cardiac signal become impossible to ignore. The lesson — that long-term safety can take decades to characterise fully — applies to newer agents too, including drugs we currently consider quite safe.

If you are currently on thioridazine

Do not stop abruptly without speaking to your prescriber. Sudden discontinuation of any antipsychotic can cause withdrawal symptoms and risks relapse. If you have been on thioridazine for a long time and it has been working, your prescriber may want to discuss whether a planned cross-titration to a newer agent makes sense, or whether to continue with careful ECG monitoring. The decision depends on your individual cardiac risk profile, response to other agents, and goals.

Practical questions to ask your prescriber

• Why am I on thioridazine specifically — what alternatives have been tried?
• What is my baseline QTc and how often will it be checked?
• Do I need an ophthalmology check?
• Are any of my other medications interacting with thioridazine?

This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling, regulatory sources, and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication.